Consistency of Label Claims of Internet-Purchased Hemp Oil and Cannabis Products as Determined using IMS and LC-MS : A Marketplace Survey

Authors

  • Ashley C Ruth Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis
  • Connie M Gryniewicz-Ruzicka Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis
  • Michael L Trehy Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis
  • Nicole Kornspan Food and Drug Administration, Office of Regulatory Affairs, OFfice of Enforcement and Import Operations, Health Fraud Unit in Silver Spring, Maryland.
  • Gary Coody Retired; formerly with Food and Drug Administration, Office of Regulatory Affairs, OFfice of Enforcement and Import Operations, Health Fraud Unit in Silver Spring, Maryland.

Keywords:

cannabinoids, hemp oil products, LC-HRMS, IMS

Abstract

In this paper we describe the use of ion mobility spectrometry (IMS) and liquid chromatography – high resolution mass spectrometry (LC-HRMS) to screen for the presence of cannabinoids and other potential hazards in a set of products with hemp oil and/or cannabinoid label claims purchased via the internet. Preliminary screening was performed using IMS to examine the products for the presence of cannabinoids, illicit drugs or undeclared pharmaceuticals before analysis by LC-HRMS to quantitatively determine the presence of four of the most common naturally occurring cannabinoids while simultaneously qualitatively screening for the presence of nine of the most common cannabinoids.  No other illicit drug or undeclared pharmaceutical was detected in any sample from IMS screening. Eighteen of twenty-three samples tested positive for the presence of at least one cannabinoid by LC-HRMS, with  three products containing less than 0.01%(w/w) of a cannabinoid. Four products with explicit CBD label claims were found to not contain any CBD, while three products featured levels of cannabinoids below label claim.

https://doi.org/10.21423/jrs-v04n03p001 (DOI assigned 5/31/2019)

Author Biographies

Ashley C Ruth, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis

Dr. Ruth is a chemist at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis in St. Louis, Missouri.

Connie M Gryniewicz-Ruzicka, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis

Dr. Ruzicka is a chemist at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis in St. Louis, Missouri.

Michael L Trehy, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis

Dr. Trehy is an acting branch chief at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis in St. Louis, Missouri.

Nicole Kornspan, Food and Drug Administration, Office of Regulatory Affairs, OFfice of Enforcement and Import Operations, Health Fraud Unit in Silver Spring, Maryland.

Ms. Kornspan is a consumer safety officer at the Food and Drug Administration, Office of Regulatory Affairs, OFfice of Enforcement and Import Operations, Health Fraud Unit in Silver Spring, Maryland.

Gary Coody, Retired; formerly with Food and Drug Administration, Office of Regulatory Affairs, OFfice of Enforcement and Import Operations, Health Fraud Unit in Silver Spring, Maryland.

Mr. Coody is retired, formerly the health fraud coordinator at the Food and Drug Administration, Office of Regulatory Affairs, OFfice of Enforcement and Import Operations, Health Fraud Unit in Silver Spring, Maryland.

References

R. Caballero, State Legislative Activity Re Marijuana: Results of the November 2014 Elections and Proposed Bills for 2015. (2015).

W. Hall, M. Weier, Assessing the public health impacts of legalizing recreational cannabis use in the USA, Clinical pharmacology and therapeutics 97.

R. Room, Legalizing a market for cannabis for pleasure: Colorado,Washington, Uruguay and beyond, Addiction 109.

A. A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, R. Mechoulam, Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb, Trends in Pharmacological Sciences 30 (2009) 515.

Z. Walsh, R. Callaway, L. Belle-Isle, R. Capler, R. Kay, P. Lucas, et al., Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use, The International journal on drug policy 24.

R. Vandrey, J. C. Raber, M. E. Raber, Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products, Journal of the American Medical Association 313 (2015) 2491.

Health Canada. Industrial Hemp Regulations SOR/98-156.(2015).

S. Sonnberg, S. Armenta, S. Garrigues, M. de la Guardia, Detection of tetrahydrocannabinol residues on hands by ion-mobility spectrometry (IMS). Correlation of IMS data with saliva analysis, Analytical and bioanalytical chemistry 407 (2015) 5999.

A. B. Kanu, C. Wu, J. Hill, H. H., Rapid preseparation of interferences for ion mobility spectrometry, Analytica chimica acta 610 (2008) 125.

S. Gwak, J. R. Almirall, Rapid screening of 35 new psychoactive substances by ion mobility spectrometry (IMS) and direct analysis in real time (DART) coupled to quadrupole time-of-flight mass spectrometry (QTOF-MS), Drug testing and analysis 7 (2015) 884.

S. Armenta, S. Garrigues, M. de la Guardia, J. Brassier, M. Alcala, M. Blanco, et al., Detection and characterization of emerging psychoactive substances by ion mobility spectrometry, Drug testing and analysis 7 (2015) 280.

M. Grabenauer, W. L. Krol, J. L. Wiley, B. F. Thomas, Analysis of Synthetic Cannabinoids Using High-Resolution Mass Spectrometry and Mass Defect Filtering: Implications for Nontargeted Screening of Designer Drugs, Analytical chemistry 84 (2012) 5574.

S. Arzhantsev, X. Li, J. F. Kauman, Rapid limit tests for metal impurities in pharmaceutical materials by X-ray fluorescence spectroscopy using wavelet transform filtering, Anal Chem 83 (2011) 1061.

D. J. Mans, R. J. Callahan, J. D. Dunn, C. M. Gryniewicz-Ruzicka, Rapidscreening detection of acetildenafils, sildenafils and avanafil by ion mobility spectrometry, Journal of pharmaceutical and biomedical analysis 75 (2013) 153.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Elemental Impurities (Q3D).(2014).

Downloads

Published

2016-07-22

Issue

Section

Scientific Articles